Pandemic Flu Prep: An Interview With Novartis Vaccines Chief Andrin Oswald
Novartis recently produced its first batch of H1N1 vaccine, but winning approval for a cell-based vaccine could prove challenging in the U.S.
Novartis recently produced its first batch of H1N1 vaccine, but winning approval for a cell-based vaccine could prove challenging in the U.S.